NICE issues final draft guidance recommending enzalutamide for prostate cancer
People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the cytotoxic drug docetaxel, should be given access to enzalutamide through the NHS, NICE has confirmed in final draft guidance. Enzalutamide is also known as Xtandi and manufactured by Astellas Pharma.
People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the cytotoxic drug docetaxel, should be given access to enzalutamide through the NHS, NICE has confirmed in final draft guidance. Enzalutamide is also known as Xtandi and manufactured by Astellas Pharma.
- New hope for prostate cancer sufferers after NHS U-turn Daily Telegraph
No comments:
Post a Comment